Polyglutamine Aggregation Inhibitor, PGL-135 (CAS 26278-83-1)
QUICK LINKS
PGL-135, recognized as a polyglutamine aggregation inhibitor, is used in research focused on protein misfolding and aggregation, phenomena associated with several neurodegenerative disorders. By inhibiting the aggregation of proteins with expanded polyglutamine tracts, Polyglutamine Aggregation Inhibitor, PGL-135 serves as a tool to investigate the molecular pathways involved in the formation of neuronal inclusion bodies. The compound is particularly relevant in the study of disorders where polyglutamine expansion leads to protein aggregation and subsequent neuronal toxicity. Polyglutamine Aggregation Inhibitor, PGL-135 is also applied to explore the potential mechanisms of protein homeostasis and the cellular stress response. Additionally, it aids in the development of high-throughput screening assays for compounds that can modulate protein aggregation processes.
Polyglutamine Aggregation Inhibitor, PGL-135 (CAS 26278-83-1) References
- Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. | Heiser, V., et al. 2002. Proc Natl Acad Sci U S A. 99 Suppl 4: 16400-6. PMID: 12200548
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Polyglutamine Aggregation Inhibitor, PGL-135, 5 mg | sc-204207 | 5 mg | $104.00 |